Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [

Somatostatin analogues (SSA) are frequently used in the treatment of neuroendocrine tumours. Recently, [ 77 patients were examined with standardised [18F]SiTATE-PET/CT within clinical routine: 40 patients with long-acting SSAs up to 28 days prior to PET/CT examination and 37 patients without pre-treatment with SSAs. Maximum and mean standardized uptake values (SUVmax and SUVmean) of tumours and metastases (liver, lymphnode, mesenteric/peritoneal and bones) as well as representative background tissues (liver, spleen, adrenal gland, blood pool, small intestine, lung, bone) were measured, SUV ratios (SUVR) were calculated between tumours/metastases and liver, likewise between tumours/metastases and corresponding specific background, and compared between the two groups. SUVmean of liver (5.4 ± 1.5 vs. 6.8 ± 1.8) and spleen (17.5 ± 6.8 vs. 36.7 ± 10.3) were significantly lower (p < 0.001) and SUVmean of blood pool (1.7 ± 0.6 vs. 1.3 ± 0.3) was significantly higher (p < 0.001) in patients with SSA pre-treatment compared to patients without. No significant differences between tumour-to-liver and specific tumour-to-background SUVRs were observed between both groups (all p > 0.05). In patients previously treated with SSAs, a significantly lower SSR expression ([18F]SiTATE uptake) in normal liver and spleen tissue was observed, as previously reported for 68Ga-labelled SSAs, without significant reduction of tumour-to-background contrast. Therefore, there is no evidence that SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT.

Informations de copyright

Copyright © 2023 Eschbach, Hofmann, Späth, Sheikh, Delker, Lindner, Jurkschat, Wängler, Wängler, Schirrmacher, Tiling, Brendel, Wenter, Dekorsy, Zacherl, Todica, Ilhan, Grawe, Cyran, Unterrainer, Rübenthaler, Knösel, Paul, Boeck, Westphalen, Spitzweg, Auernhammer, Bartenstein, Unterrainer and Beyer.

Déclaration de conflit d'intérêts

CA has received research contracts Novartis, lecture honorarium Ipsen, Novartis, Advanced Accelerator Applications and honoraria for advisory boards Advanced Accelerator Applications. HI has received research contracts Novartis. LB received honoraria for advisory boards Bayer, Advanced Accelerator Applications and is a Novartis Radiopharmaceuticals GmbH employee since 10/2022. CW has received honoraria from Amgen, Bayer, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, SIRTeX, Taiho; served on advisory boards for Bayer, BMS, Celgene, Servier, Shire/Baxalta, Rafael Pharmaceuticals, RedHill, Roche, has received travel support by Bayer, Celgene, RedHill, Roche, Servier, Taiho and research grants institutional by Roche. CW serves as an officer for European Society of Medical Oncology ESMO, Deutsche Krebshilfe DKH, Arbeitsgemeinschaft internistische Onkologie AIO. The remaining authors declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.